TransMedics Group, Inc. (TMDX) は上場企業です ヘルスケア セクターの Medical - Devices 業界で事業展開. 本社所在地は Andover, MA, アメリカ. 現CEOは Waleed H. Hassanein.
TMDX を有する IPO日 2019-05-02, 728 名の正社員, に上場 NASDAQ Global Market, 時価総額 $3.97B.
TransMedics Group, Inc. is a commercial-stage medical technology company headquartered in Andover, Massachusetts, focused on transforming organ transplant therapy for end-stage organ failure patients globally. The company develops and commercializes the Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring platform that uses proprietary technology to maintain near-physiologic conditions for donor organs outside the human body. Its product portfolio includes OCS LUNG for lung preservation, OCS Heart for cardiac preservation, and OCS Liver for hepatic preservation, each designed to improve transplant outcomes and expand the pool of viable organs. Founded in 1998, TransMedics addresses critical challenges in organ transplantation through innovative ex vivo organ preservation technology.